title: Abnormal endometrial development occurs during the luteal phase of nonsupplemented donor cycles treated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists.
authors.forename: Efstratios M
authors.initials: EM
authors.lastname: Kolibianakis
authors.forename: Claire
authors.initials: C
authors.lastname: Bourgain
authors.forename: Peter
authors.initials: P
authors.lastname: Platteau
authors.forename: Carola
authors.initials: C
authors.lastname: Albano
authors.forename: Andre C
authors.initials: AC
authors.lastname: Van Steirteghem
authors.forename: Paul
authors.initials: P
authors.lastname: Devroey
mesh_terms: D000328:Adult; D004717:Endometrium / Q000166:cytology* / Q000187:drug effects*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D006801:Humans; D008183:Luteal Phase; D008597:Menstrual Cycle / Q000187:drug effects; D008938:Mitosis / Q000187:drug effects; D009865:Oocytes; D010062:Ovulation Induction; D011994:Recombinant Proteins / Q000627:therapeutic use; D014019:Tissue Donors; D020858:Tissue and Organ Harvesting
chemical_list: D011994:Recombinant Proteins; D007987:Gonadotropin-Releasing Hormone; D005640:Follicle Stimulating Hormone